CKS1B: A Potential Drug Target and Biomarker (G1163)

Target Name: CKS1B

NCBI ID: G1163

CKS1B

CKS1B: A Potential Drug Target and Biomarker

Introduction

CKS1B (CDC2-associated protein CKS1) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a key regulator of cell signaling pathways, and its dysfunction has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CDC2 is a transcription factor, which regulates the expression of genes involved in cell signaling pathways. CKS1B is a critical regulator of CDC2-mediated signaling pathways, and its dysfunction in these pathways has been implicated in the development and progression of many diseases.

Potential Drug Target

One of the most promising aspects of CKS1B is its potential as a drug target. The development of small molecules that can specifically modulate CKS1B activity has the potential to treat a wide range of diseases.

For example, CKS1B has been shown to play a role in the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. High levels of CKS1B expression have also been observed in various types of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

In addition to its role in disease, CKS1B has also been shown to be a potential biomarker. The levels of CKS1B have been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker Potential

The potential use of CKS1B as a biomarker is based on the fact that it is a protein that is expressed in various tissues of the body, and its levels can be measured and correlated with the presence or absence of disease.

For example, one study showed that CKS1B levels were elevated in the brains of patients with Alzheimer's disease, and that these levels were associated with the severity of the disease. Another study also found that CKS1B levels were elevated in the blood of patients with breast cancer , and that these levels were associated with the size and stage of the cancer.

In addition to its potential as a biomarker, CKS1B has also been shown to be a useful target for small molecules. The CKS1B gene has been shown to be responsive to a wide range of small molecules, including inhibitors of tyrosine kinase, inhibitors of protein kinase , and modulators of the transcription factor CDC2.

Conclusion

In conclusion, CKS1B is a protein that has the potential to be a drug target and biomarker in a wide range of diseases. Its role as a regulator of cell signaling pathways and its expression in various tissues make it an attractive target for small molecules. Further research is needed to fully understand the function and potential of CKS1B in disease.

Protein Name: CDC28 Protein Kinase Regulatory Subunit 1B

Functions: Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function

The "CKS1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKS1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets